Three Seasons Wealth’s Charles River Laboratories CRL Stock Holding History

Three Seasons Wealth’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$590K	Buy	+1,999	New	+$527K	0.05%	115

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Three Seasons Wealth's CRL Position: Q3 2026 in Review

Three Seasons Wealth opened a new position in Charles River Laboratories (CRL) in Q3 2026: 1,999 shares worth $590K. The stake represents 0.05% of the portfolio and ranks #115 among its holdings.

379 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

Three Seasons Wealth held 1,999 shares of Charles River Laboratories worth $590K as of Q3 2026.
Charles River Laboratories was a new Three Seasons Wealth position in Q3 2026.
Charles River Laboratories made up 0.05% of Three Seasons Wealth's portfolio in Q3 2026, its #115 holding.
379 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Three Seasons Wealth's 13F filing for Q3 2026, filed 3 Nov 2026.